FDA improperly denied Ranbaxy, Ivax rights to exclusivity

Share this article:
A federal judge ruled the FDA improperly denied generic drugmakers Ranbaxy and Ivax rights to 180 days of marketing exclusivity for generic forms of Merck's cholesterol-lowering drug Zocor (simvastatin). He threw out the FDA's decision to grant Merck's request to delist two patents.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.